4,578 results match your criteria Tardive Dyskinesia


How to Evaluate Patients and Educate Them About Self-Examinations for Tardive Dyskinesia Between Appointments.

J Clin Psychiatry 2021 Mar 9;82(1). Epub 2021 Mar 9.

Dauten Family Center for Bipolar Treatment Innovation and the Depression Clinical and Research Program, Massachusetts General Hospital, and Department of Psychiatry, Harvard Medical School, Boston.

Patients taking dopamine-blocking agents such as antipsychotics are at risk for developing tardive dyskinesia. In this webcast, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia, how to observe patients (whether in person or via telemedicine), and how to educate patients and families about TD. Read More

View Article and Full-Text PDF

Atypical antipsychotics: Managing adverse effects.

Perspect Psychiatr Care 2021 May 5. Epub 2021 May 5.

Department of Health and Community Systems, University of Pittsburgh, School of Nursing, Pittsburgh, Pennsylvania, USA.

Purpose: The purpose of this article is to provide an overview of common adverse effects and management strategies related to atypical antipsychotic use.

Conclusions: Atypical antipsychotics are commonly prescribed. While effective, atypical antipsychotics are associated with metabolic syndrome, extrapyramidal symptoms, and tardive dyskinesia, among others adverse effects. Read More

View Article and Full-Text PDF

Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia.

Pharmacol Biochem Behav 2021 Apr 29;206:173193. Epub 2021 Apr 29.

Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. Electronic address:

Tardive dyskinesia (TD) is a side effect associated with the long-term use of certain antipsychotics. Considering the modulatory role of the endocannabinoid system upon dopaminergic neurotransmission, the present study tested the hypothesis that increasing endocannabinoid (anandamide and 2-arachidonoylglycerol) levels attenuates haloperidol-induced TD (vacuous chewing movements, VCMs) in male Wistar rats. The animals received administration of chronic haloperidol (38 mg/kg; 29 days) followed by acute FAAH (URB597, 0. Read More

View Article and Full-Text PDF

Improvement of Inpatient Psychiatric Facility Quality Reporting program measure: Screening for metabolic disorders through pharmacy collaborative practice agreement.

J Am Pharm Assoc (2003) 2021 Apr 21. Epub 2021 Apr 21.

Background: Second-generation antipsychotics are associated with lower risks of extrapyramidal symptoms, including tardive dyskinesia. However, many second-generation antipsychotics are associated with metabolic adverse effects, including weight gain, impaired blood glucose control, and hyperlipidemia. Metabolic monitoring for patients prescribed antipsychotic medication is 1 of several measures of the Centers for Medicare & Medicaid Services' Inpatient Psychiatric Facility Quality Reporting program. Read More

View Article and Full-Text PDF

Comparison of Safety and Tolerability of Deutetrabenazine During Titration and Maintenance in Patients with Tardive Dyskinesia.

CNS Spectr 2021 Apr;26(2):164-180

Teva Pharmaceutical Industries Ltd., West Chester, PA, USA.

Background: Deutetrabenazine is approved to treat tardive dyskinesia (TD) in adults and is titrated weekly by 6 mg/day, from 12 to 48 mg/day, based on dyskinesia control and tolerability. This analysis compared the safety of deutetrabenazine during titration versus maintenance.

Methods: Safety was assessed during titration versus maintenance using integrated data from two 12-week placebo-controlled studies (ARM-TD and AIM-TD) and the open-label extension study. Read More

View Article and Full-Text PDF

[Mental disorders in the dental practice. Psychotic disorders in the schizophrenia spectrum].

Authors:
M van der Gaag

Ned Tijdschr Tandheelkd 2021 Apr;128(4):197-201

Patients with a psychotic disorder have certain symptoms, movement disorders resulting from the pharmacological effects of medication. Knowing about this is important to the patients' dental treatment. A very small group will present with delusions about teeth or the benevolent or malevolent intentions of the dentist. Read More

View Article and Full-Text PDF

Effect of Varenicline on Tardive Dyskinesia: A Pilot Study.

Clin Psychopharmacol Neurosci 2021 May;19(2):355-360

Behavioral Health Service, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.

Objective: Although evidence implicates striatal cholinergic impairment as a mechanism underlying tardive dyskinesia, trials of nonspecific cholinergic agents have been inconclusive. As a partial agonist at specific nicotinic receptor subtypes, varenicline reduces drug-induced dyskinesias in animal models suggesting promise as a treatment for tardive dyskinesia.

Methods: Three schizophrenia patients with tardive dyskinesia who were smokers underwent an open trial of varenicline. Read More

View Article and Full-Text PDF

ATP1A3-Related Disorders: An Ever-Expanding Clinical Spectrum.

Front Neurol 2021 1;12:637890. Epub 2021 Apr 1.

Department of Neurology and Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.

The Na+/K+ ATPases are Sodium-Potassium exchanging pumps, with a heteromeric α-β-γ protein complex. The α3 isoform is required as a rescue pump, after repeated action potentials, with a distribution predominantly in neurons of the central nervous system. This isoform is encoded by the ATP1A3 gene. Read More

View Article and Full-Text PDF

Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonists-induced orofacial dyskinesia.

JCI Insight 2021 Apr 15. Epub 2021 Apr 15.

Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.

Antipsychotics often cause tardive dyskinesia, an adverse symptom of involuntary hyperkinetic movements. Analysis of the U.S. Read More

View Article and Full-Text PDF

Treatment of tardive dyskinesia: a review and update for dermatologists managing delusions of parasitosis.

J Dermatolog Treat 2021 Mar 30:1-5. Epub 2021 Mar 30.

Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.

Introduction: This article introduces to the dermatology provider two medications for the treatment of tardive dyskinesia (TD), which were the first medications approved by the US FDA specifically for the treatment of TD. In addition to describing these two new medications, this article will also provide a focused review of the pathogenesis of TD, as well as non-FDA-approved treatments, which have been tried prior to the advent of these medications.

Methods: A PubMed search was conducted and articles were reviewed by the senior authors and included if they were relevant for dermatologists regarding etiology, symptoms, risk, and treatment of TD. Read More

View Article and Full-Text PDF

A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Schizophr Bull 2021 Mar 23. Epub 2021 Mar 23.

Institute of Psychiatry, Psychology and Neuroscience, King's College London, 16 De Crespigny Park, Camberwell, London SE5 8AF, UK.

The process of stopping antipsychotics may be causally related to relapse, potentially linked to neuroadaptations that persist after cessation, including dopaminergic hypersensitivity. Therefore, the risk of relapse on cessation of antipsychotics may be minimized by more gradual tapering. There is converging evidence that suggests that adaptations to antipsychotic exposure can persist for months or years after stopping the medication-from animal studies, observation of tardive dyskinesia in patients, and the clustering of relapses in this time period after the cessation of antipsychotics. Read More

View Article and Full-Text PDF

Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults.

Expert Rev Endocrinol Metab 2021 Mar 19;16(2):25-35. Epub 2021 Mar 19.

Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, USA.

: Gastroparesis (GP) is characterized by delayed gastric emptying in the absence of mechanical obstruction. About 75% of GP patients are females. Diabetes and idiopathic are the two commonest etiologies of GP. Read More

View Article and Full-Text PDF

Clinical development of valbenazine for tics associated with Tourette syndrome.

Expert Rev Neurother 2021 Apr 1;21(4):393-404. Epub 2021 Apr 1.

Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA, USA.

: Significant need exists for effective, well-tolerated pharmacologic treatments for Tourette syndrome (TS). Medications that inhibit vesicular monoamine transporters (i.e. Read More

View Article and Full-Text PDF

Movement disorders in psychiatric patients.

BMJ Neurol Open 2020 1;2(2):e000057. Epub 2020 Dec 1.

Neurosciences, Monash Medical Centre Clayton, Clayton, Victoria, Australia.

The observability of movement gives it advantages when trying to draw connections between brain and mind. Disturbed motor function pervades schizophrenia, though it is difficult now to subtract the effects of antipsychotic treatment. There is evidence from patients never exposed to these drugs that dyskinesia and even parkinsonism are to some degree innate to schizophrenia. Read More

View Article and Full-Text PDF
December 2020

Benign Presentation Following Massive Deutetrabenazine Overdose.

Cureus 2021 Jan 24;13(1):e12886. Epub 2021 Jan 24.

Emergency Medicine, Wayne State University Detroit Medical Center, Detroit, USA.

Deutetrabenazine (DTBZ) (Austedo®) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, which acts by blocking dopamine release and other monoamines from neuronal vesicles. Although this drug is considered the first-line treatment for tardive dyskinesia (TD), VMAT2 inhibition has also been shown to improve patients' symptoms with Huntington's disease-induced chorea. We present the case of a 59-year-old woman with a history of TD, who presented to the emergency department following massive DTBZ ingestion. Read More

View Article and Full-Text PDF
January 2021

Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate.

S Afr J Psychiatr 2021 11;27:1568. Epub 2021 Jan 11.

Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Background: Concern for the development of extrapyramidal side effects (EPSEs) represents a barrier to the routine use of long-acting injectable (LAI) antipsychotic medication in patients with first-episode schizophrenia (FES). Flupenthixol decanoate is a first-generation antipsychotic, which is readily available in the public healthcare system in South Africa.

Aim: The aim of this study was to describe the nature, occurrence and severity of EPSEs and their impact on patients with FES over 12 months of treatment with flupenthixol decanoate (fluanxol depot). Read More

View Article and Full-Text PDF
January 2021

Patient perspective of tardive dyskinesia: results from a social media listening study.

BMC Psychiatry 2021 02 15;21(1):94. Epub 2021 Feb 15.

Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, CA, 92130, USA.

Background: Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged exposure to dopamine receptor blocking agents such as antipsychotics. With the expanding use of antipsychotics, research is needed to better understand patient perspectives of TD, which clinical assessments may fail to capture. Social media listening (SML), which is recognized by the US FDA as a method that can advance ongoing efforts for more patient-focused drug development, has been used to understand patient experiences in other disease states. Read More

View Article and Full-Text PDF
February 2021

Recent discussions on dopamine supersensitivity psychosis: Eight points to consider when diagnosing treatment-resistant schizophrenia.

Curr Neuropharmacol 2021 Jan 25. Epub 2021 Jan 25.

Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba. Japan.

Dopamine supersensitivity psychosis is a clinical concept characterized by an unstable psychotic state and tardive dyskinesia in schizophrenia patients at the chronic stage. This state is thought to be induced by a compensatory upregulation of dopamine D2 receptors, which is provoked by long-term and/or high-dose medications. Recent clinical data suggest that patients who responded well to medication but later exhibit dopamine supersensitivity develop tolerance to antipsychotics' effects and eventually transit to treatment-resistant schizophrenia, indicating that dopamine supersensitivity could be an etiology contributing to treatment-resistant schizophrenia. Read More

View Article and Full-Text PDF
January 2021

Withania Somnifera in Neurological Disorders: Ethnopharmacological Evidence, Mechanism of Action and its Progress in Delivery Systems.

Curr Drug Metab 2021 Feb 3. Epub 2021 Feb 3.

Pharmacology Division, CSIR-Central Drug Research Institute, Sitapur Road, Lucknow 226031, . India.

Background: The underlying cause of major neurodegenerative disorders remains a health-care mystery. The thoroughly investigated causes include oxidative stress, inflammation, environmental factor, mitochondrial dysfunction, and irregular neuronal protein aggregation. Withania somnifera has been used for more than 2500 years as a useful medicinal plant to improve disease defense, prevent aging, rejuvenate the body in a vulnerable situation, and generate a feeling of mental well-being. Read More

View Article and Full-Text PDF
February 2021

Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia.

Neurotox Res 2021 Jun 1;39(3):774-786. Epub 2021 Feb 1.

Department of Psychiatry, Yuan-Shan Br. of Taipei Veteran General Hospital, 26604, Yilan County, Taiwan, Republic of China.

Animal models of haloperidol (HAL)-induced neurotoxicity and orofacial dyskinesia (OD) have long been used to study human tardive dyskinesia (TD). Similar to patients with TD, these models show strong pathophysiological characteristics such as striatal oxidative stress and neural cytoarchitecture alteration. Naringin (NAR), a bioflavonoid commonly found in citrus fruits, has potent antioxidative, anti-inflammatory, antiapoptotic, and neuroprotective properties. Read More

View Article and Full-Text PDF

Botulinum Toxin in Movement Disorders: An Update.

Toxins (Basel) 2021 Jan 8;13(1). Epub 2021 Jan 8.

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.

Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson's disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Read More

View Article and Full-Text PDF
January 2021

Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia.

Behav Brain Res 2021 Mar 5;402:113098. Epub 2021 Jan 5.

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, ON, Canada. Electronic address:

Background: Antipsychotics are a cornerstone of pharmacological treatment of schizophrenia. Improved understanding of the dose-response relationship of antipsychotics in terms of efficacy, adverse effects, and mortality can help to optimize the pharmacological treatment of schizophrenia.

Methods: This narrative literature review summarizes current evidence on the relationship of antipsychotic dose with efficacy, adverse effects, and mortality in patients with schizophrenia. Read More

View Article and Full-Text PDF

Recognition and Treatment of Tardive Dyskinesia in Individuals with Intellectual Disability.

Case Rep Psychiatry 2020 11;2020:8886980. Epub 2020 Dec 11.

University Hospital and Medical Center, Tamarac, FL, USA.

Individuals with intellectual disability (ID) commonly suffer from comorbid psychiatric and behavioral disorders that are frequently treated by antipsychotic medications. All individuals exposed to first- and second/third- generation antipsychotics are at risk for developing tardive dyskinesia (TD), characterized by abnormal, involuntary movements of the mouth/tongue/jaw, trunk, and extremities. TD can be highly disruptive for affected individuals and their caregivers, causing embarrassment, isolation, behavioral disturbances, and reduced functioning and quality of life. Read More

View Article and Full-Text PDF
December 2020

Resolution of tardive tremor after bilateral subthalamic nucleus deep brain stimulation placement.

Surg Neurol Int 2020 16;11:444. Epub 2020 Dec 16.

Department of Neurosurgery, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States.

Background: Tardive tremor (TT) is an underrecognized manifestation of tardive syndrome (TS). In our experience, TT is a rather common manifestation of TS, especially in a setting of treatment with aripiprazole, and is a frequent cause of referrals for the evaluation of idiopathic Parkinson disease. There are reports of successful treatment of tardive orofacial dyskinesia and dystonia with deep brain stimulation (DBS) using globus pallidus interna (GPi) as the primary target, but the literature on subthalamic nucleus (STN) DBS for tardive dyskinesia (TD) is lacking. Read More

View Article and Full-Text PDF
December 2020

Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia.

J Med Econ 2021 Jan-Dec;24(1):103-113

Neurocrine Biosciences, Inc, San Diego, CA, USA.

Aims: To evaluate clinical and economic outcomes associated with valbenazine compared with deutetrabenazine in patients with tardive dyskinesia (TD) using a model that accounts for multiple dimensions of patient health status.

Materials And Methods: A discretely integrated condition event model was developed to evaluate the cost-effectiveness of treatment with valbenazine and deutetrabenazine in a synthetic cohort of 1,000 patients with TD who were receiving antipsychotic medication to treat an underlying psychiatric disorder. Clinical inputs were derived from relevant clinical trials or from publicly available sources. Read More

View Article and Full-Text PDF
January 2021

Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia.

Tremor Other Hyperkinet Mov (N Y) 2020 12 16;10:56. Epub 2020 Dec 16.

James J and Joan A Gardner Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, OH, US.

Background: Copulatory or pelvic thrusting dyskinesia is a subtype of tardive dyskinesia (TD) which is caused by exposure to dopamine blocking agents.

Phenomenology Shown: A man exhibiting rhythmic, stereotypical pelvic thrusting movements.

Educational Value: Recognition of copulatory dyskinesia as a distinctive iatrogenic disorder helps prevent unnecessary investigations and guides the implementation of corrective strategies. Read More

View Article and Full-Text PDF
December 2020

Covert Dyskinesia With Aripiprazole: Tip of the Iceberg? A Case Report and Literature Review.

J Clin Psychopharmacol 2021 Jan/Feb 01;41(1):67-70

From the Department of Psychiatry and Behavioral Health, Penn State College of Medicine, Hershey, PA.

Background: Tardive dyskinesia (TD) is an involuntary movement disorder most commonly involving the tongue, lips, and face and less commonly the trunk and limbs. Although TD is historically associated with conventional antipsychotics, it still occurs with newer agents. Covert dyskinesia (CD), a form of TD, occurs after the discontinuation of antipsychotics, and it differs from other withdrawal emergent dyskinesia by its persistence for more than 8 to 12 weeks after discontinuation of dopamine receptor-blocking agents. Read More

View Article and Full-Text PDF
December 2020

Psychotropic Medications-Induced Tardive Dyskinesia and Associated Factors Among Patients with Mental Illness in Ethiopia.

Clin Pharmacol 2020 1;12:179-187. Epub 2020 Dec 1.

Department of Psychiatry, Faculty of Medical Science, Institute of Health, Jimma University, Jimma, Ethiopia.

Background: Tardive dyskinesia (TD) remains a significant burden especially among patients taking psychotropic medications, and it is associated with adverse effects that can lead to subjective suffering, stigma, poor compliance to medication, and poor quality of life. However, it is unrecognized and overlooked in clinical settings. So, this study aimed to assess the magnitude of tardive dyskinesia and associated factors among mentally ill patients attending follow-up treatment at Jimma University Medical Center Psychiatry clinic, Jimma, Southwest Ethiopia, 2019. Read More

View Article and Full-Text PDF
December 2020

Abnormal functional connectivity of motor circuit in the schizophrenic patients with tardive dyskinesia: A resting-state fMRI study.

Neurosci Lett 2021 01 3;742:135548. Epub 2020 Dec 3.

Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, PR China. Electronic address:

Background: Animal and neuroimaging studies suggest that the volume of the motor-circuit region decreases in tardive dyskinesia (TD). This study examined the differences in functional connectivity within the motor circuit of patients with schizophrenia with and without TD to further clarify how the dysfunction is related to the pathogenesis of TD.

Methods: Functional magnetic resonance images were taken of 56 schizophrenic patients with TD (TD group), 64 without TD (non-TD group), and 68 healthy controls (HC group). Read More

View Article and Full-Text PDF
January 2021